Martin Ingelsson
Has grant
Specialist
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Close
Development of biomarkers for Parkinson´s disease and other neurodegenerative disorders with Lewy body pathology
Open Date: 2014-01-01
Close Date: 2015-01-01
Grant: Close
Investigation on the propagation and aggregation of alpha-synuclein - implications for future immunotherapy in Lewy body disorders
Open Date: 2014-01-01
Close Date: 2015-01-01
Grant: Close
Alpha-synuclein oligomers as a novel target for therapy and diagnostics in Parkinson’s disease and related disorders
Open Date: 2014-01-01
Close Date: 2015-01-01
Grant: Close
Alfa-synuklein - ny målmolekyl för framtida behandling av Parkinsons sjukdom
Open Date: 2014-01-01
Close Date: 2015-01-01
Grant: Close
Utveckling av monoklonala antikroppar mot alfa-synuklein protofibriller - nya möjligheter till diagnostik och behandling av Parkinsons sjukdom och relaterade tillstånd
Open Date: 2012-01-01
Close Date: 2015-01-01
Articles (12)
Year:
2026
Body mass index (BMI), type 2 diabetes (T2D) and associated cardiometabolic features modify Alzheimer’s disease (AD) risk, yet shared mechanisms remain poorly understood. Using sex- and age-stratified genotyping data for BMI and T2D, we investigate how these traits converge on shared genetic pathways to AD risk. Employing multi-trait, machine learning and single-cell transcriptomics, we identify sex-specific cardiometabolic liability linked to higher BMI-associated risk in women and T2D-driven risk in men. Variant-level analyses reveal AD risk associates with genetically-driven hypotension and hypoglycaemia. We identify 35 putative effector genes in seven independent loci colocalizing between BMI/T2D and AD, mapping to peripheral immune and metabolic tissues and cell-types. Pathway enrichment identifies druggable targets in calcium and potassium channel signaling. Across 81 approved drugs modulating shared risk genes, levosimendan - a calcium sensitizer for heart failure - inhibits tau oligomerization and emerges as a repurposing candidate. These findings elucidate sex-specific cardiometabolic drivers of AD, identify actionable biological pathways, and reveal drug candidates for AD prevention and treatment.
Year:
2026
Year:
2025
Background Plasma phosphorylated tau 217 (p-tau 217 ) is a robust biomarker of Alzheimer's disease (AD) pathology. However, its full potential as a dynamic marker has still not been verified in very old persons, i.e., those with the highest incidence of AD. Objective To examine the cross-sectional and longitudinal associations between plasma p-tau 217 concentration and cerebrospinal fluid (CSF) AD biomarkers. Further, to investigate the performance of p-tau 217 as a predictor of amyloid status in a cohort of very old men. Methods CSF AD biomarkers were analyzed in thirty-five 89-year-old men. Amyloid-β (Aβ) positivity was defined according to CSF Aβ 42 level. Plasma p-tau 217 concentration was measured at the mean age of 82, 87, and 91. Incident dementia diagnoses in survivors were identified through medical records up to the age of 102. Results Plasma p-tau 217 strongly correlated with CSF Aβ 42 concentration in Aβ-positive (n = 16, Spearman ρ : rho = −0.63, p = 0.009) but not in Aβ-negative (n = 19, rho = 0.111, p = 0.652) men and predicted Aβ status (area under the curve, AUC 0.91). Plasma p-tau 217 increased over ten years in the Aβ-positive group, while it remained unchanged in the negative group (p = 0.018). Conclusions Our findings indicate that plasma p-tau 217 is a predictor of brain Aβ deposition also in very old individuals.
Year:
2025
Year:
2025
Year:
2025
Cerebrospinal fluid (CSF) amyloid beta (Aβ42), total tau (t-tau), and phosphorylated tau (p-tau181) are well accepted markers of Alzheimer’s disease. We performed a GWAS meta-analysis including 18,948 individuals of European and 416 non-European ancestry. We identified 12 genome-wide significant loci across all three biomarkers, eight of them novel. We replicated the association of CSF biomarkers with APOE , CR1 , GMNC/CCDC50 and C16orf95/MAP1LC3B . Novel loci included BIN1 for Aβ42 and GNA12, MS4A6A, SLCO1A2 with both t-tau and p-tau181, as well as additional loci on chr. 8, near ANGPT1 and chr. 9 near SMARCA2 . We also demonstrated that these variants were not only associated with CSF level of the three biomarkers but also showed significant association with AD risk, disease progression and/or brain amyloidosis. The associated genes are implicated in lipid metabolism independent APOE , as well as autophagy and brain volume regulation driven by t-tau and p-tau181 dysregulation.
Year:
2025
Among the more than 90 identified genetic risk loci for late-onset Alzheimer’s disease (AD) and related dementias, the apolipoprotein E gene ( APOE ) ɛ2/ɛ3/ɛ4 polymorphisms remains the longstanding benchmark for genetic disease risk with a consistently large effect across studies 1–10 . Despite this massive signal, the exact mechanisms for how ɛ4 increases and for how ɛ2 decreases dementia risk is not well-understood. Importantly, recent trials of anti-amyloid therapies suggest less efficacy and higher risks of severe side effects in ε4 carriers 11–13 , hampering the treatment of those with the highest unmet need. To improve our understanding of the genetic architecture of AD in the context of its main genetic driver, we performed genome-wide association studies (GWASs) stratified by ε4 and ε2 carrier status. Such insights may help to understand and overcome side effects, to impact clinical trial enrolment strategies, and to create the scientific basis for targeted mechanism-driven therapies in neurodegenerative diseases.
Year:
2025
Neuroinflammation, particularly that involving reactive microglia, the brain’s resident immune cells, is implicated in the pathogenesis of major neurodegenerative diseases. However, early markers of this process are in high demand. Multiple studies have reported changes in ribosomal protein (RP) expression during neurodegeneration, but the significance of these changes remains unclear. Ribosomes are evolutionarily conserved protein synthesizing machines, and although commonly viewed as invariant, accumulating evidence suggest functional ribosome specialization through variation in their protein composition. By analyzing cell type-specific translating mRNAs from mouse brains, we identify distinct RP expression patterns between neurons, astrocytes, and microglia, including neuron-specific RPs, Rpl13a and Rps10 . We also observed complex expression relationships between RP paralogs and their canonical counterparts, suggesting regulated mechanisms for generating heterogeneous ribosomes. Analysis across brain regions revealed that Rplp0 and Rpl13a , commonly used normalization references, show heterogeneous expression, raising important methodological considerations for gene expression studies. Importantly, we show that Rps24 , an essential ribosome component that undergoes alternative splicing to produce protein variants with different C-termini, exhibits striking cell type-specific isoform expression in brain. The Rps24c isoform is predominantly expressed in microglia and is increased by neuroinflammation caused by aging, neurodegeneration, or inflammatory chemicals. We verify increased expression of S24-PKE, the protein variant encoded by Rps24c , in brains with Alzheimer’s disease, Parkinson’s disease, and Huntington’s disease, and relevant mouse models, using isoform-specific antibodies. These findings establish heterogeneous RP expression as a feature of brain cell types and identify Rps24c /S24-PKE as a novel marker for neuroinflammation and neurodegeneration.
Year:
2025
Year:
2023
Year:
2023
Year:
2023
Collaborators (90)
Stefanie Heilmann-Heimbach
Head of Laboratory, Research Group Leader
University Hospital Bonn
Ruth Frikke-Schmidt
Professor, Chief Physician, MD PhD DMSc
-
Maria Jesús Bullido Gómez-Heras
Researcher
Universidad Autónoma de Madrid
Olga E Titova
Assistant Professor
Uppsala Universitet Medicinska fakulteten
Bernardino Ghetti
Distinguished Professor
Indiana University School of Medicine
Pau Pastor
Institut Català de la Salut
Eloy Rodriguez-Rodríguez
Instituto de Investigación Marqués de Valdecilla
innocenzo rainero
University of Turin
Henrik Zetterberg
Professor
University of Gothenburg
Agustín Ruiz Laza
Director of the Biology Core
University of Texas Health Science Center at San Antonio
Harro Seelaar
Neurologist
Erasmus MC
Michael Heneka
Director
University of Bonn
Philippe Amouyel
Full Professor
Centre Hospitalier Régional Universitaire de Lille
Jesper Qvist Thomassen
Senior Scientist
Rigshospitalet
Johannes Kornhuber
-
Walker Jackson
Senior lecturer
Linköping University
Ruth Loos
The Charles Bronfman Professor in Personalized Medicine
Københavns Universitet
Henne Holstege
Professor
KU Leuven
Marco Spallazzi
Adjunt professor
University of Parma
Markus Nöthen
Professor, Director
University Hospital Bonn
Benedetta Nacmias
University of Florence
Suzanne Schindler
Associate Professor
Washington University in St. Louis
Lucilla Parnetti
Professor of Neurology
University of Perugia
Caroline Jonson
University of California, San Francisco
Pieter Jelle Visser
Karolinska Institutet
Jordi Pérez-Tur
Coordinador Adjunto al Área Global Vida
Agencia Estatal Consejo Superior de Investigaciones Científicas
Patrizia Mecocci
Director
Karolinska Institutet
Caroline Graff
Professor,MD PhD
Karolinska Institutet
Henna Martiskainen
University of Eastern Finland
Amy Kit Yu Fu
Research Professor
The Hong Kong University of Science and Technology
Arvid Rongve
Professor
University of Bergen
Jean-Charles Lambert
Head of research unit
INSERM
Betty Tijms
Senior researcher
VU medisch centrum
Joel Watts
Associate Professor
University of Toronto
Simon Laws
Professor
Edith Cowan University
Nancy Yuk-Yu Ip
The Morningside Professor of Life Science
The Hong Kong University of Science and Technology
Katja Scheffler
Associate Professor
Norwegian University of Science and Technology
Takeshi Ikeuchi
Professor
Brain Research Institute, Niigata University
Jonathan Vogelgsang
Harvard University
Ciyang Wang
Washington University in St. Louis
Geir Selbaek
Professor
University of Oslo
Timothy Hohman
Professor
Vanderbilt University Medical Center
Pablo Mir
-
Norbert Scherbaum
Professor for Clinical Addiction Research
University of Duisburg-Essen Faculty of Medizin
Tormod Fladby
Professor ll of Neurology
University of Oslo
Margda Waern
University of Gothenburg
Gesine Paul
Lund University
Muhammad Ali
Assistant Professor
Washington University in St. Louis
Bradley Hyman
Professor
Harvard University
Andrew Saykin
Professor and Director, Center for Neuroimaging and Indiana Alzheimer's Disease Research Center
Indiana University School of Medicine
Srdjan Djurovic
Professor at University of Oslo
University of Oslo
Sami Heikkinen
Research Director
University of Eastern Finland
Najaf Amin
Associate Professor
University of Oxford
Wiesje van der Flier
Scientific director
VU medisch centrum
Peter Holmans
Professor of Biostatistics and Genetic Epidemiology
Cardiff University
Dag Sehlin
Professor
Uppsala Universitet Medicinska fakulteten
David M. Holtzman
Washington University School of Medicine
Dan Rujescu
Head of Clinical Division of General Psychiatry
Medical University of Vienna
Alessio Squassina
Dalhousie University
Carole Dufouil
Director of research
INSERM
Virginia M-Y Lee
Professor
University of Pennsylvania
Robert Perneczky
Professor
Ludwig-Maximilians-Universität München
Hilkka Soininen
Kuopio University Hospital
María José Romero Lado
University of Copenhagen
Gael Nicolas
PUPH
University of Rouen
Åsa Mackenzie
Senior Lecturer
Lund University
Riccardo E Marioni
University of Edinburgh
Anssi Lipponen
University of Eastern Finland
Patrick Kehoe
Academic , Gestetner Professor of Translational Dementia Research
University of Bristol
Alison Goate
Professor and Chair
Icahn School of Medicine at Mount Sinai
Alfredo Ramirez
University of Texas Health Science Center at San Antonio
INGVILD SALTVEDT
Professor
Norwegian University of Science and Technology
Dag Aarsland
Professor and Head of Department
King’s College London
Daniela Galimberti
Associate Professor
Università degli Studi di Torino
Carlos Cruchaga
Professor
Washington University in St. Louis
Ole A. Andreassen
Oslo University Hospital
Lucio Tremolizzo
Associate Professor of Neurology
University of Milano-Bicocca
Valentina Escott-Price
Professor
Cardiff University
Ville Leinonen
Professor
University of Eastern Finland
Lutz Froelich
Head
Zentralinstitut für Seelische Gesundheit
Rebecca Sims
Senior Research Fellow
Cardiff University
Barbara Borroni
Docenti di ruolo di IIa fascia
University of Brescia
Lars Bertram
Professor of Genome Analytics
University of Lübeck
Jose Luis Royo
University of Malaga
Mikko Hiltunen
University of Eastern Finland
Cornelia Van Duijn
Professor
University of Oxford
Alberto Lleó
Director
Hospital de la Santa Creu i Sant Pau
Sterling Johnson
Professor
University of Wisconsin-Madison
Menghan Liu
Washington University in St. Louis
Tuomas Kilpeläinen
Assistant professor
Københavns Universitet
Make your next move.
Prepare your application
Review drafts before you send them.